PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
Michael E. Stokes(Ithaka Harbors), David Surguladze(Intellicell Biosciences (United States)), Nupur Ballal(Intellicell Biosciences (United States)), Nandita Bose(FuelCell Energy (United States)), Leyi Shen(Intellicell Biosciences (United States)), Sharon Huang(Intellicell Biosciences (United States)), Verónica Calvo(Intellicell Biosciences (United States)), Matthew J. Betzenhauser(Buffalo BioLabs), Sho Fujisawa(New York University), Mark J. Mulvihill(FuelCell Energy (United States)), Jennifer Gasparek(Buffalo BioLabs), Alan C. Rigby(FuelCell Energy (United States)), Kirk A. Staschke(Indiana University School of Medicine), Eric S. Lightcap(Minneapolis Business College), S. Taylor(Pharmaron (United Kingdom)), Crissy Dudgeon(Rutgers, The State University of New Jersey)
Cited by 27
Related Papers
Wip1 Phosphatase Modulates ATM-Dependent Signaling Pathways
|Molecular Cell|2006|347
Hearing Loss Raises Excitability in the Auditory Cortex
|Journal of Neuroscience|2005|292
Multivalent Small-Molecule Pan-RAS Inhibitors
|Cell|2017|283
Pancreatic cancer modeling using retrograde viral vector delivery and in vivo CRISPR/Cas9-mediated somatic genome editing
|Genes & Development|2015|278
Probing the roles of SUMOylation in cancer cell biology by using a selective SAE inhibitor
|Nature Chemical Biology|2017|228